These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1362374)

  • 1. Spin echo nuclear magnetic resonance studies on intact erythrocytes: changes in cellular metabolism as a consequence of carbimazole therapy.
    Reglinski J; Smith WE; Wilson R; Buchanan LM; McKillop JH; Thomson JA
    Clin Endocrinol (Oxf); 1992 Oct; 37(4):319-24. PubMed ID: 1362374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy.
    Mastorakos G; Doufas AG; Mantzos E; Mantzos J; Koutras DA
    J Endocrinol Invest; 2003 Oct; 26(10):979-84. PubMed ID: 14759070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid function tests during carbimazole therapy.
    Scott DL; Tymms DJ; Taylor MA; Chapman C
    Postgrad Med J; 1980 Dec; 56(662):838-41. PubMed ID: 6894979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum thyroid hormones and TSH response to TRH during treatment of Graves' disease by carbimazole (author's transl)].
    Lorcy Y; Heim J; Auvray E; Allannic H
    Ann Endocrinol (Paris); 1979; 40(4):441-2. PubMed ID: 117739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid stimulating immunoglobulin bioactivity during carbimazole therapy as measured by the cytochemical bioassay.
    Prentice MG; Rayman GA; Alaghband-Zadeh J; Wise PH
    J Endocrinol Invest; 1987 Oct; 10(5):483-9. PubMed ID: 2892877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
    N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbimazole and the autoimmune response in Graves' disease.
    McGregor AM; Petersen MM; McLachlan SM; Rooke P; Smith BR; Hall R
    N Engl J Med; 1980 Aug; 303(6):302-7. PubMed ID: 6247656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism.
    Abbara A; Clarke SA; Brewster R; Simonnard A; Eng PC; Phylactou M; Papadopoulou D; Izzi-Engbeaya C; Sam AH; Wernig F; Jonauskyte E; Comninos AN; Meeran K; Kelsey TW; Dhillo WS
    Front Endocrinol (Lausanne); 2020; 11():286. PubMed ID: 32477269
    [No Abstract]   [Full Text] [Related]  

  • 12. Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease.
    MacFarlane IA; Davies D; Longson D; Shalet SM; Beardwell CG
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):557-61. PubMed ID: 6411390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole.
    Grebe SK; Feek CM; Ford HC; Fagerström JN; Cordwell DP; Delahunt JW; Toomath RJ
    Clin Endocrinol (Oxf); 1998 May; 48(5):585-92. PubMed ID: 9666870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased activated T-lymphocytes and normal thyrotropin receptor antibody levels in Graves' disease in long-term remission.
    Peakman M; Hussain M; Cundy T; Vergani D
    J Clin Lab Immunol; 1989 Sep; 30(1):1-5. PubMed ID: 2577115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
    Lucas A; Salinas I; Rius F; Pizarro E; Granada ML; Foz M; Sanmartí A
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2410-3. PubMed ID: 9253309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thyrotrophin response to thyrotrophin releasing hormone during treatment in patients with Graves' disease.
    Haug E; Frey HM; Sand T
    Acta Endocrinol (Copenh); 1977 Jun; 85(2):335-44. PubMed ID: 405834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.